New Online Social Network, BioMedExperts, to Improve Collaboration Among Medical Researchers

Collexis Holdings, Inc. (OTCBB: CLXS), a leading developer of high definition search and knowledge discovery software, announced the debut of BioMedExperts - the first online social network of its kind to improve collaboration among researchers and therefore advance medical science. Collexis launched the new service with more than 1.4 million pre-generated profiles of its expected users from across 120 countries and expects to grow by another two million profiles over the next few months.

An agreement with Dell Healthcare and Life Sciences helped make BioMedExperts possible. Dell supplied the computer hardware for the service and will help market BioMedExperts.

"The ability for researchers to collaborate across scientific disciplines is becoming more and more critical," said James Coffin, Ph.D., vice president and general manager of Dell Healthcare and Life Sciences. "By connecting biologists, chemists, clinical researchers and other scientists from across the globe, BioMedExperts can play a key role in enabling a new wave of modern science and have tremendous impact on progress in biomedical research."

The new service will allow life sciences professionals to connect with each other, share data, collaborate more efficiently and conduct deep research across thousands of sources.

"Where first generation social networks like Facebook and LinkedIn require users to enter data, BioMedExperts is a life science open platform that goes to the next level – it continuously captures the research activity of experts worldwide, serving as a definitive source to identify relationships to others within the community, either by topic or geography," said Bill Kirkland, CEO of Collexis. When researchers log on to the service, which is entirely free, they will have access to approximately 12 million pre-established network connections, automatically generated from more than 6 million scientific publications from 6,500 journals. BioMedExperts encompasses almost every published researcher in the biomedical sciences field worldwide.

Searching by name, keyword or location, scientists can quickly see their own "network" of co-authors ...and even co-authors of their co-authors. The site makes it easy for researchers and scientists to analyze all associated professional connections within the network as well as find new potential research partners, co-authors, etc.

BioMedExperts includes tools that allow users to:

  • Search the network of profiles and articles by expert name or keyword and analyze the profiles of more than 1.4 million scientists by expertise, region and more
  • Customize their own profiles
  • Communicate with other members of BioMedExperts – users can invite others to their own personal network and email experts from within the entire BioMedExperts community to cultivate and grow professional affiliations
  • Set up article alerts – users can receive alerts on new articles by topic or by name (for example, users can easily track articles published by co-authors

BioMedExperts is based on Collexis' proprietary Fingerprint technology, an enterprise research tool that serves as the basis of search and retrieval solutions for such leading organizations as Harvard University, Johns Hopkins, the Mayo Clinic and The National Institutes of Health.

Kirkland added that BioMedExperts is the first in a series of professional social networks that the company plans to introduce over the next couple of years that utilizes the proprietary technology.

For further information, please visit:
http://www.biomedexperts.com

About Collexis Holdings, Inc.
Named a Trend-Setting product of 2007 by KMWorld, Collexis Holdings, Inc., a leading developer of high definition search and knowledge discovery software since 1999, is headquartered in Columbia, South Carolina (USA), with operations in Geldermalsen, The Netherlands and Cologne, Germany. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Merck & Co.; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. For more information, please visit www.collexis.com.

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...